New Drug
GM-XANTHO
INDICATION
Atopic Dermatitis
MECHANISM
- Anti-inflammatory
- Decrease the expression of Th2 cytokines IL-10, IL-4, IgE and restore Th1/Th2 balance by suppressing the overexpression of keratinocytes
STATUS
- Phase II
ADVANTAGES
- Botanical new drugs have high barriers to entry, and raw materials are difficult to obtain.
- The effect is as good as steroids but not recur in AD
- Safety and long-term use
MARKET
The Global Data estimates that in 2027, the sales were total $18.3B for atopic dermatitis worldwide.
- The allergic reaction is a series of allergic and inflammatory reactions initiated by over-expression of the Th2 pathway in the body.
GM-XANTHO is a botanical new drug for the treatment of Atopic Dermatitis. It can decrease the expression of Th2 cytokines IL-10, IL-4, IgE and restore Th1/Th2 balance by suppressing the overexpression of Cytokines of keratinocyte cells. GM-XANTHO potentially has both therapeutic and preventive effects in allergic disease. - GM-XANTHO has completed CMC, which has manufactured in accordance with GMP/PIS specifications. GM-XANTHO has completed pre-clinical pharmacology, pharmacokinetics and toxicity tests to confirm the efficacy of GM-XANTHO in the treatment of atopic dermatitis and has low side effects.